Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05088512
Other study ID # 1207
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 23, 2021
Est. completion date January 20, 2023

Study information

Verified date March 2023
Source Asfendiyarov Kazakh National Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To research for a genetic marker of bronchial asthma, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with bronchial asthma and normal control will be performed.


Description:

Unrelated Kazaks subjects who have bronchial asthma were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with bronchial asthma and normal control subjects free of bronchial asthma


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date January 20, 2023
Est. primary completion date January 20, 2023
Accepts healthy volunteers No
Gender All
Age group 5 Years to 65 Years
Eligibility Inclusion Criteria: - Persons with bronchial asthma confirmed by a doctor; - The age of the patients is from 5 to 60 years; - Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs. - Persons who are able and willing to provide written informed consent; - Persons capable and willing to comply with the research protocol; Exclusion Criteria: - Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; - Pregnant or lactating women; - Tuberculosis of any localization in the active phase and in history; - Severe and decompensated diseases of the liver and kidneys, cardiovascular system; - Severe and decompensated course of endocrine diseases; - Autoimmune diseases; - Systemic diseases; - Oncological diseases;

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample

Locations

Country Name City State
Kazakhstan Kazakhstan Almaty

Sponsors (1)

Lead Sponsor Collaborator
Asfendiyarov Kazakh National Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of SNPs associated with bronchial asthma Using SNPsto identify candidate genes associate with bronchial asthma 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02934945 - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients Phase 4
Completed NCT02561351 - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation N/A
Recruiting NCT01759472 - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test N/A
Completed NCT01918293 - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult N/A
Completed NCT01203904 - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation N/A
Completed NCT01762917 - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing N/A
Completed NCT00536731 - Symbicort Rapihaler Therapeutic Equivalence Study Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00930826 - Childhood Asthma and Schooling: The Truth Unveiled N/A
Completed NCT00327028 - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma Phase 4
Completed NCT00413387 - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®) Phase 3
Completed NCT00153283 - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma Phase 4
Completed NCT00950794 - Study of Salmeterol (SN408D) for Adult Asthma Phase 4
Completed NCT00142025 - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma Phase 4
Completed NCT00153270 - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma Phase 4
Completed NCT03450434 - XC8 in the Treatment of Patients With Bronchial Asthma Phase 2
Recruiting NCT05189613 - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis N/A
Recruiting NCT04128111 - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed NCT06326632 - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma N/A
Completed NCT01232322 - Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation N/A